Looking Back: Ovarian Cancer in 2017

Video

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses recent exciting developments in the ovarian cancer field.

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, shares his thoughts on exciting developments in the ovarian cancer field from 2017. Three poly (ADP-ribose) polymerase (PARP) inhibitors were recently approved for people who have ovarian cancer which are administered orally, so they are convenient to take, and may be taken for a long time. He believes these drugs have great potential in ovarian cancer treatment.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
Image of a checklist that says FDA.

Tisotumab Vedotin-tftv Approved by FDA in Advanced Cervical Cancer

April 29th 2024
Article

The FDA has approved tisotumab vedotin-tftv for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Inconsistent Symptom Clusters Warrant Routine Assessments in Older Patients With Cancer

Inconsistent Symptom Clusters Warrant Routine Assessments in Older Patients With Cancer

April 25th 2024
Article

Older patients with cancer demonstrated a moderate to high symptom burden, leading to the need for routine symptom assessments and tailored management interventions.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

FDA Grants Full Approval to Mirvetuximab Soravtansine for Pretreated Gynecologic Cancers

FDA Grants Full Approval to Mirvetuximab Soravtansine for Pretreated Gynecologic Cancers

March 22nd 2024
Article

Mirvetuximab soravtansine received full approval from the FDA for pretreated adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

FDA Approves Onbody Administration System for Pegfigrastim Biosimilar

FDA Approves Onbody Administration System for Pegfigrastim Biosimilar

January 6th 2024
Article

The Food and Drug Administration approved an on-body delivery system for pegfilgrastim-cbqv, a biosimilar of pegfilgrastim.

© 2024 MJH Life Sciences

All rights reserved.